Currently, addressing contributing conditions (hypothyroidism, hypogonadism, and adrenal insufficiency), managing nutrition impact symptoms leading to decreased oral intake (nausea, constipation, dysgeusia, stomatitis, mucositis, pain, fatigue, depressed mood, or anxiety), and the addition of pharmacologic agents when appropriate (progesterone analog, corticosteroids, and olanzapine) is recommended. In Japan, the clinical practice has changed based on the availability of Anamorelin, a ghrelin receptor agonist that improved lean body mass, weight, and appetite-related quality of life (QoL) compared to a placebo, in phase III trials...In the future, a single therapeutic agent or perhaps multiple medications targeting the various mechanisms of CC may prove to be an effective strategy. Ideally, these medications should be incorporated into a multimodal interdisciplinary approach that includes exercise and nutrition.

2 days ago

Review • Journal

GDF15 (Growth differentiation factor 15)

olanzapine

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)

P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024

8 days ago

Trial completion date • Metastases

olanzapine

10d

Impact of intraoperative dexmedetomidine on postoperative delirium and pro-inflammatory cytokine levels in elderly patients undergoing thoracolumbar compression fracture surgery: A prospective, randomized, placebo-controlled clinical trial. (PubMed, Medicine (Baltimore))

Dexmedetomidine is effective in reducing early POD in elderly patients post-thoracolumbar compression fracture surgery. It also decreases IL-6 and TNF-α levels, indicating its potential in managing postoperative inflammatory responses. Treatment with 0.5 mM DEX significantly modulated Phospho-ERK1/2 and Phospho-JNK expressions in postoperative CSF samples, indicating a dose-dependent effect on reducing inflammation. This study contributes to understanding DEX's role in improving postoperative outcomes in elderly patients.

10 days ago

Clinical • Journal • Surgery

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MAPK1 (Mitogen-activated protein kinase 1) • IL1B (Interleukin 1, beta) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8)

olanzapine

12d

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors (clinicaltrials.gov)

P2, N=66, Recruiting, OHSU Knight Cancer Institute | Suspended --> Recruiting | N=44 --> 66 | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Jun 2025

12 days ago

Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases

olanzapine

18d

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov)

P3, N=1351, Completed, University of Rochester NCORP Research Base | Recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024

18 days ago

Trial completion • Trial completion date

Akynzeo oral (netupitant/palonesteron FDC) • olanzapine

22d

SOLARIS: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (clinicaltrials.gov)

P3, N=675, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Mar 2024

22 days ago

Trial completion date • Trial primary completion date

olanzapine

25d

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine (clinicaltrials.gov)

P4, N=13, Terminated, Sumitomo Pharma (Suzhou) Co., Ltd. | N=162 --> 13 | Active, not recruiting --> Terminated; Company's business decision

25 days ago

Enrollment change • Trial termination

olanzapine

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial (clinicaltrials.gov)

P3, N=72, Recruiting, Tan Tock Seng Hospital | Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024

1 month ago

Trial completion date • Trial primary completion date

olanzapine

Detoxification From the Lipid Tract (clinicaltrials.gov)

P4, N=1, Completed, Pachankis, Yang I., M.D.

1 month ago

New P4 trial

olanzapine

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)

P1, N=95, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

olanzapine

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (clinicaltrials.gov)

P3, N=87, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

olanzapine

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)

P1, N=116, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

olanzapine

2ms

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia (clinicaltrials.gov)

P1, N=19, Completed, Sumitomo Pharma America, Inc. | Recruiting --> Completed | N=60 --> 19

2 months ago

Trial completion • Enrollment change

olanzapine

2ms

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens (clinicaltrials.gov)

P3, N=627, Not yet recruiting, Fudan University

2 months ago

New P3 trial • Head-to-Head

dexamethasone • Akynzeo oral (netupitant/palonesteron FDC) • olanzapine

2ms

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)

P1, N=36, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

olanzapine

2ms

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)

P1, N=95, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.

2 months ago

New P1 trial

olanzapine

2ms

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)

P1, N=116, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.

2 months ago

New P1 trial

olanzapine

2ms

Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)

P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Feb 2024 --> May 2024

2 months ago

Trial initiation date

olanzapine

3ms

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov)

P3, N=62, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting | N=170 --> 62

3 months ago

Enrollment closed • Enrollment change

carboplatin • paclitaxel • fosaprepitant • olanzapine • ondansetron

3ms

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)

P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Feb 2024 --> Jun 2024

3 months ago

Trial completion date • Metastases

olanzapine

3ms

Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov)

P2/3, N=40, Completed, Charite University, Berlin, Germany | Unknown status --> Completed

3 months ago

Trial completion

olanzapine • riluzole

3ms

P3, N=640, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

olanzapine

3ms

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)

P1, N=36, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.

3 months ago

New P1 trial

olanzapine

3ms

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia (clinicaltrials.gov)

P1, N=17, Completed, Minerva Neurosciences | Recruiting --> Completed | Phase classification: P1b --> P1

3 months ago

Trial completion • Phase classification

olanzapine

4ms

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients (clinicaltrials.gov)

P2, N=150, Active, not recruiting, Central Institute of Mental Health, Mannheim | Trial completion date: Aug 2022 --> Jun 2025 | Trial primary completion date: May 2022 --> Dec 2024

4 months ago

Trial completion date • Trial primary completion date

olanzapine

4ms

LBL: Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (clinicaltrials.gov)

P1, N=20, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

olanzapine

4ms

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov)

P3, N=52, Completed, Rush University Medical Center | N=429 --> 52

4 months ago

Enrollment change

melphalan • aprepitant oral • olanzapine

4ms

P3, N=1600, Recruiting, University of Rochester NCORP Research Base | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Apr 2024

4 months ago

Trial completion date • Trial primary completion date

Akynzeo oral (netupitant/palonesteron FDC) • olanzapine

4ms

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (clinicaltrials.gov)

P3, N=87, Not yet recruiting, M.D. Anderson Cancer Center

4 months ago

New P3 trial

olanzapine

4ms

Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)

P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

olanzapine

4ms

MAIA: Maternal And Infant Antipsychotic Study (clinicaltrials.gov)

P=N/A, N=200, Recruiting, Icahn School of Medicine at Mount Sinai

4 months ago

Trial completion date • Trial primary completion date

olanzapine

5ms

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard (clinicaltrials.gov)

P1, N=31, Completed, Sumitomo Pharma America, Inc. | Recruiting --> Completed

5 months ago

Trial completion

olanzapine

5ms

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia (clinicaltrials.gov)

P1, N=60, Recruiting, Sumitomo Pharma America, Inc. | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Oct 2023 --> Mar 2024

5 months ago

Trial completion date • Trial primary completion date

olanzapine

5ms

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)

P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024

5 months ago

Trial completion date • Trial primary completion date • Metastases

olanzapine

5ms

Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)

P4, N=80, Not yet recruiting, Icahn School of Medicine at Mount Sinai

5 months ago

Trial completion date • Trial initiation date • Trial primary completion date

olanzapine

6ms

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine (clinicaltrials.gov)

P1, N=24, Completed, Response Pharmaceuticals | Not yet recruiting --> Completed

6 months ago

Trial completion

APOB (Apolipoprotein B)

olanzapine

6ms

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). (PubMed, Br J Cancer)

DEX-sparing is an alternative option for patients receiving cisplatin; however, this revised administration schedule should be applied on an individual basis after a comprehensive evaluation.

6 months ago

P3 data • Journal

B3GAT1 (Beta-1,3-Glucuronyltransferase 1)

cisplatin • olanzapine

6ms

Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)

P4, N=80, Not yet recruiting, Icahn School of Medicine at Mount Sinai

6 months ago

New P4 trial

olanzapine

6ms

MAIA: Maternal And Infant Antipsychotic Study (clinicaltrials.gov)

P=N/A, N=200, Recruiting, Icahn School of Medicine at Mount Sinai | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

olanzapine

6ms

The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset (clinicaltrials.gov)

P=N/A, N=300, Not yet recruiting, Peking University

6 months ago

New trial

olanzapine

6ms

A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy. (PubMed, BMC Med Genomics)

This study found that gene polymorphisms, including HTR3B (rs1062613, rs1176719, rs2276303), HTR3B (rs45460698, rs7943062), HTR3C (rs6766410), ERCC1 (rs3212986), ERCC4 (rs744154) and MTHFR(rs1801131), may be independent prognostic factors for CINV.

6 months ago

Journal

ERCC1 (Excision repair cross-complementation group 1) • MTHFR (Methylenetetrahydrofolate Reductase) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit)

cisplatin • olanzapine